. "I, V" . . "Psychiatrie" . . "RIV/00023752:_____/12:43913804" . . . "Kope\u010Dek, Miloslav" . "H\u00F6schl, Cyril" . "Teoretick\u00E9 a klinick\u00E9 aspekty pod\u00E1v\u00E1n\u00ED dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik"@cs . "\u010Cl\u00E1nek pod\u00E1v\u00E1 p\u0159ehled o poznatc\u00EDch a zku\u0161enostech s u\u017Eit\u00EDm dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik (DPIA). Auto\u0159i odhaduj\u00ED, \u017Ee preskripce DPIA v \u010CR tvo\u0159\u00ED asi 6 % v\u0161ech antipsychotik. Zahrani\u010Dn\u00ED odhady p\u0159edpokl\u00E1daj\u00ED, \u017Ee ve Finsku u\u017E\u00EDv\u00E1 DPIA cca 10 % pacient\u016F, zat\u00EDmco ve Velk\u00E9 Brit\u00E1nii je to 25-33 %. Lze p\u0159edpokl\u00E1dat, \u017Ee zv\u00FD\u0161en\u00ED preskripce DPIA by mohlo sni\u017Eovat m\u00EDru relaps\u016F a rehospitalizac\u00ED, jak to nazna\u010Duj\u00ED n\u011Bkter\u00E9 studie. D\u00E1le se auto\u0159i sna\u017E\u00ED definovat typ pacient\u016F ide\u00E1ln\u00EDch pro nejnov\u011Bj\u0161\u00ED DPIA. Olanzapin pamo\u00E1t m\u016F\u017Ee b\u00FDt ide\u00E1ln\u00ED volbou pro pacienty s p\u0159edchoz\u00ED odpov\u011Bd\u00ED na olanzapin \u010Di MARTA antipsychotika jako\u017E i pro non-adherentn\u00ED pacienty citliv\u00E9 na ne\u017E\u00E1douc\u00ED p\u0159\u00EDznaky extrapyramidov\u00E9 a endokrinn\u00ED (prolaktin). C\u00EDlovou skupinu u\u017Eivatel\u016F paliperidon palmit\u00E1tu je mo\u017En\u00E9 definovat p\u0159edchoz\u00ED odpov\u011Bd\u00ED na SDA antipsychotika a citlivost\u00ED k sedaci, zv\u00FD\u0161en\u00ED hmotnosti \u010Di anticholinergn\u00EDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dink\u016Fm." . . . . . "adverse effects; indication; long acting injection antipsychotics"@en . "[162FCFC42236]" . "Theoretical and clinical aspects of long acting injection antipsychotics"@en . "16" . . . "\u010Cl\u00E1nek pod\u00E1v\u00E1 p\u0159ehled o poznatc\u00EDch a zku\u0161enostech s u\u017Eit\u00EDm dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik (DPIA). Auto\u0159i odhaduj\u00ED, \u017Ee preskripce DPIA v \u010CR tvo\u0159\u00ED asi 6 % v\u0161ech antipsychotik. Zahrani\u010Dn\u00ED odhady p\u0159edpokl\u00E1daj\u00ED, \u017Ee ve Finsku u\u017E\u00EDv\u00E1 DPIA cca 10 % pacient\u016F, zat\u00EDmco ve Velk\u00E9 Brit\u00E1nii je to 25-33 %. Lze p\u0159edpokl\u00E1dat, \u017Ee zv\u00FD\u0161en\u00ED preskripce DPIA by mohlo sni\u017Eovat m\u00EDru relaps\u016F a rehospitalizac\u00ED, jak to nazna\u010Duj\u00ED n\u011Bkter\u00E9 studie. D\u00E1le se auto\u0159i sna\u017E\u00ED definovat typ pacient\u016F ide\u00E1ln\u00EDch pro nejnov\u011Bj\u0161\u00ED DPIA. Olanzapin pamo\u00E1t m\u016F\u017Ee b\u00FDt ide\u00E1ln\u00ED volbou pro pacienty s p\u0159edchoz\u00ED odpov\u011Bd\u00ED na olanzapin \u010Di MARTA antipsychotika jako\u017E i pro non-adherentn\u00ED pacienty citliv\u00E9 na ne\u017E\u00E1douc\u00ED p\u0159\u00EDznaky extrapyramidov\u00E9 a endokrinn\u00ED (prolaktin). C\u00EDlovou skupinu u\u017Eivatel\u016F paliperidon palmit\u00E1tu je mo\u017En\u00E9 definovat p\u0159edchoz\u00ED odpov\u011Bd\u00ED na SDA antipsychotika a citlivost\u00ED k sedaci, zv\u00FD\u0161en\u00ED hmotnosti \u010Di anticholinergn\u00EDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dink\u016Fm."@cs . "The article informs about knowledge and experiences with long acting injection antipsychotics (LAI-A). Authors estimate that prescriptions of LAI-A in the Czech Republic represent 6% of all antipsychotics. There are estimations that 10% of patients with schizophrenia use LAI-A in Finland and about 25-33 % in Great Britain. We hypothesize that increased prescription of LAI-A could lead to decreased relapse rate and rehospitalisation what some studies indicate. Further, authors try to define who is ideal patient for the use of the most new LAI-A. The olanzapine pamoat might be ideal for patiens with previous response to oral olanzapine or other MARTA antipsychotics and for non-adherent patients sensitive to extrapyramidal and prolactin side effects. The target group of paliperidone palmitate might be specified by previous response to SDA antipsychotics as well as sensitivity to sedation, weight gain and anticholinergic side effects."@en . "1211-7579" . "2"^^ . "RIV/00023752:_____/12:43913804!RIV13-MZ0-00023752" . "10"^^ . "Theoretical and clinical aspects of long acting injection antipsychotics"@en . . "Teoretick\u00E9 a klinick\u00E9 aspekty pod\u00E1v\u00E1n\u00ED dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik" . "2"^^ . "Teoretick\u00E9 a klinick\u00E9 aspekty pod\u00E1v\u00E1n\u00ED dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik" . . "173781" . "CZ - \u010Cesk\u00E1 republika" . "http://www.tigis.cz/images/stories/psychiatrie/2012/04/02_kopecek_psych_4-12.pdf" . . "4" . "Teoretick\u00E9 a klinick\u00E9 aspekty pod\u00E1v\u00E1n\u00ED dlouhodob\u011B p\u016Fsob\u00EDc\u00EDch injek\u010Dn\u00EDch antipsychotik"@cs . . . .